Is “test to treat” too good to be true? Does it really matter who gets credit for CRISPR? And what’s the offramp for Covid-19?
We cover all that and more this week on “The Readout LOUD,” STAT’s biotech podcast. Physician and researcher Kavita Patel joins us to explain why President Biden’s plans for Covid-19 — including an ambitious idea to distribute antiviral treatments — might not be so simple. We also discuss some milestone data in the quest to turn CRISPR into medicine and the latest twist in the quest to figure out who invented it.
For more on what we cover, here’s the news on the White House’s plans; here’s the latest on Covid-19 vaccine data; here’s more on the latest CRISPR data; here’s the story on the patent dispute; here’s where you can subscribe to the First Opinion Podcast; and here’s our complete coverage of the Covid-19 pandemic.
And if you have any feedback for us — topics to cover, guests to invite, vocal tics to cease — you can email [email protected].
Interested in sponsoring a future episode of “The Readout LOUD”? Email us at [email protected].
Create a display name to comment
This name will appear with your comment